Histocompatibility typing by cellular radioimmunoassay.

Immunogenetics

Department of Immunology, The University of Alberta, 845E Medical Sciences Building, T6G 2H7, Edmonton, Alberta, Canada.

Published: December 1978

AI Article Synopsis

  • A quantitative cellular radioimmunoassay (CRIA) was developed for histocompatibility typing using chicken red blood cells, showing high sensitivity and consistency compared to traditional hemagglutination assays.
  • The assay successfully detected low percentages (as low as 1%) of specific cells in mixed cell populations and quantitated erythrocyte chimerism in chickens that had received embryonic stem cell injections, revealing chimerism levels between 13-40%.
  • In addition, the CRIA identified tumor-specific antigens in T-cell lymphoma, with unexpected results suggesting that the binding properties of alloantibodies to certain RBC genotypes defy conventional expectations.

Article Abstract

A quantitative cellular radioimmunoassay (CRIA) for histocompatibility typing is described. Chicken red blood cells (RBC) were incubated in microtiter plates with specific anti-MHC (B) alloantisera and the alloantibody bound measured indirectly by a second binding step with(125)I-labeled rabbit anti-chicken IgG. The assay is objective, highly consistent, and three to four orders of magnitude more sensitive than conventional hemagglutination assays. The new CRIA was used to detect minor subpopulations of cells in artificial cell mixtures; as few as 1% of relevant cells were easily detected. Erythrocyte chimerism was induced following the injection of B(2)/B(2) chicken embryos with B(15)/B(21) embryonic stem cells. Five weeks after hatching, erythrocyte chimerism was precisely quantitated by comparing the reaction of RBC from the putative chimeras with artificial cell mixtures using specific anti-B(15)/B(21) alloantisera. The percent varied from 13-40% in 13 chimeric animals. The new CRIA was also used for the sensitive detection of tumor-specific antigens on a T-cell lymphoma. An unexpected finding was that anti-B(15) alloantibody bound almost as well to B(15)/B(21) heterozygous RBC as to B(15)/B(15) homozygous cells, suggesting that either the concentration or the steric arrangement of B(15) alloantigen at the erythrocyte surface may not conform to conventional expectations.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF01844008DOI Listing

Publication Analysis

Top Keywords

histocompatibility typing
8
cellular radioimmunoassay
8
alloantibody bound
8
artificial cell
8
cell mixtures
8
erythrocyte chimerism
8
cells
5
typing cellular
4
radioimmunoassay quantitative
4
quantitative cellular
4

Similar Publications

The full-length sequence of HLA-DQB1*06:304N covers the 5'-untranslated region (UTR), all introns and exons, and the 3' UTR.

View Article and Find Full Text PDF

Novel MICB alleles MICB*004:01:31, MICB*004:01:32, MICB*004:01:33 and MICB*005:02:59, were identified using next generation sequencing.

View Article and Find Full Text PDF

Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor-recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically.

View Article and Find Full Text PDF

The novel HLA-C*06:44:02 allele differs from HLA-C*06:44:01 by one synonymous nucleotide substitution in exon 2.

View Article and Find Full Text PDF

HLA-B*15:245:02Q differs from HLA-B*15:01:01:01 by two nonsynonymous nucleotides exchanges in exon 3.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!